Introduction {#section1-2050313X19838946}
============

Sclerotherapy with N-butyl-cyanoacrylate, a watery solution that polymerizes immediately when in contact with blood, is widely used for the treatment of gastric variceal bleeding. Most complications associated with cyanoacrylate injection treatment include transient fever, tissue necrosis at injection site probably leading to perforation, post-sclerotherapy ulcer, portal and splenic vein thrombosis with and without splenic infarction, and most importantly pulmonary embolism. Risk factor includes volumes and speed of injection and the size of gastric varices.^[@bibr1-2050313X19838946],[@bibr2-2050313X19838946]^ We present herein a case of pulmonary embolism following.

Case report {#section2-2050313X19838946}
===========

A 49-year-old male patient with type 2 diabetes mellitus and Child-Pugh class B alcoholic cirrhosis (MELD score 19, PT 18.5, APTT 34.1, INR 1.69) was hospitalized due to primary *Streptococcus constellatus* bacteremia, and had received penicillin G sodium treatment. Two days after hospitalizaition, he developed massive hematemesis, and emergent endoscopy was performed which revealed large gastroesophageal varices (GOVs) type 2 with blood spurting at the cardia of stomach. The patient then recieved a total of 15.6 mL of cyanoacrylate injection until bleeding was stopped ([Figure 1](#fig1-2050313X19838946){ref-type="fig"}). The following day, he developed acute progressive dyspnea with partial pressure of oxygen (PaO~2~) from arterial blood gas of 80 mmHg at room air. Acute pulmonary embolism was suspected, chest X-ray ([Figure 2](#fig2-2050313X19838946){ref-type="fig"}) and computed tomogram of pulmonary artery ([Figure 3](#fig3-2050313X19838946){ref-type="fig"}) was emergently carried out and exhibited a concentric intraluminal hyperdense filling defect within a lumen of anterior and lateral basal segmental branches of right lower pulmonary artery. Echocardiogram showed normal pulmonary pressure without cardiac abnormalities. A final diagnosis of sclerotherapy-associated pulmonary embolism was made. He was managed conservatively without anticoagulant treatment due to high risk of bleeding tendency from decompensated cirrhosis, and gradually improved and discharged home 2 weeks after hospitalization.

![Endoscopy revealed large gastroesophageal varices (GOVs) type 2 with blood spurting at the cardia of stomach, which was stopped by cyanoacrylate glue injection.](10.1177_2050313X19838946-fig1){#fig1-2050313X19838946}

![Chest X-ray revealed bilateral patchy opacity suspected pulmonary venous congestion.](10.1177_2050313X19838946-fig2){#fig2-2050313X19838946}

![CTPA showed concentric intraluminal hyperdense filling defect within anterior and lateral basal segmental branches of right lower pulmonary artery, and suspected sclerotherapy-related pulmonary embolism.](10.1177_2050313X19838946-fig3){#fig3-2050313X19838946}

Discussion {#section3-2050313X19838946}
==========

Pulmonary embolism is a rare but life-threatening complication of sclerotherapy. In a review article, Saraswat and Verma^[@bibr3-2050313X19838946]^ concluded that the incidence of embolization ranged from 0.5% to 4.3%. Alexander et al.^[@bibr4-2050313X19838946]^ described that the risk of embolism included the volume of glue, injection rate, and the size of gastric varices. Another study showed that the volume of glue was associated with the risk of embolization.^[@bibr5-2050313X19838946]^ Our patient illustrates that the risk of pulmonary embolism is associated with the large volume of cyanoacrylate.

The pathophysiology of pulmonary embolism during endoscopic sclerotherapy is associated with a portosystemic vascular shunt ([Figure 4](#fig4-2050313X19838946){ref-type="fig"}), espectially a gastrosplenorenal shunt which reopens from embryonic vascular pathways. This shunt is a high flow shunt portal circulation to systemic circulation and may carry clots or embolic material from injected varices to the systemic venous flow, right heart, and then pulmonary circulation.^[@bibr6-2050313X19838946]^

![Preoperative contrast-enhanced abdominal CT scan from this patient shows portosystemic shunt. (a) Dilated gastroepipoic vein. (b) Dilated left gastric vein. (c) Esophageal varice.](10.1177_2050313X19838946-fig4){#fig4-2050313X19838946}

There were 17 cases of sclerotherapy-associated pulmonary embolism, including our patient ([Table 1](#table1-2050313X19838946){ref-type="table"}).^[@bibr5-2050313X19838946][@bibr6-2050313X19838946][@bibr7-2050313X19838946][@bibr8-2050313X19838946][@bibr9-2050313X19838946][@bibr10-2050313X19838946][@bibr11-2050313X19838946][@bibr12-2050313X19838946][@bibr13-2050313X19838946][@bibr14-2050313X19838946]--[@bibr15-2050313X19838946]^ The median age of the patients was 56 years (range 11--77 years, IQR 41 and 60 years), and 58.8% were male. The etiology of cirrhosis includes alcohol (3, 17.6%), hepatitis B (3, 17%), hepatitis C (2, 11.7%), others (3, 17.6%), and unknown cause (6, 35.2%). Cyanoacrylate was used as sclerosing agent in all patients and the mean volume of the injected cyanoacrylate mixed with lipiodol was 5.5 ml (range 1--12 mL). Clinical manifestations of sclerotherapy-related pulmonary embolism is similar to pulmonary embolism, which varies from asymptomatic to severe hypoxia with cardiac arrest. Onset of symptoms also varies from immediate after procedure to late onset up to 10 days. The location of pulmonary embolism is mostly the bilateral pulmonary arteries (9, 53%). Of 17 patients with available information, 14 (82%) received only supportive care and 2 recieved cardiopulmonary resuscitation due to variceal bleeding and massive pulmonary embolism. One patient (6%) died from massive pulmonary embolism.

###### 

Previous report of sclerotherapy-related pulmonary embolism.

![](10.1177_2050313X19838946-table1)

  No.                                                       Sex      Age   Underlying disease       Clinical feature                    Diag-nosis   Sclerotherapy   Onset of pulmonary embolism following sclerotherapy   Location of emboli       Treatment        Outcome                
  --------------------------------------------------------- -------- ----- ------------------------ ----------------------------------- ------------ --------------- ----------------------------------------------------- ------------------------ ---------------- ---------------------- ------------------------------------
  1\. Hwang et al.^[@bibr5-2050313X19838946]^               Female   42    N/A                      N/A                                 GV           Cyanoacrylate   4                                                     N/A                      N/A              Supportive treatment   Recovery
  2\. Hwang et al.^[@bibr5-2050313X19838946]^               Male     48    N/A                      N/A                                 GV           Cyanoacrylate   3                                                     N/A                      N/A              Supportive treatment   Recovery
  3\. Hwang et al.^[@bibr5-2050313X19838946]^               Male     56    N/A                      N/A                                 GV           Cyanoacrylate   4.5                                                   N/A                      N/A              Supportive treatment   Recovery
  4\. Hwang et al.^[@bibr5-2050313X19838946]^               Male     60    N/A                      N/A                                 GV           Cyanoacrylate   4                                                     N/A                      N/A              Supportive treatment   Recovery
  5\. Hwang et al.^[@bibr5-2050313X19838946]^               Male     46    N/A                      N/A                                 GV           Cyanoacrylate   3.5                                                   N/A                      N/A              Supportive treatment   Recovery
  6\. Hwang et al.^[@bibr5-2050313X19838946]^               Female   57    N/A                      N/A                                 GV           Cyanoacrylate   6                                                     N/A                      N/A              Supportive treatment   Recovery
  7\. Marion-Audibert et al.^[@bibr6-2050313X19838946]^     N/A      77    Alcoholic cirrhosis      Hematemesis                         GOV2         Cyanoacrylate   6                                                     A few minutes            Bilateral PA     CPR                    Died of severe persistant bleeding
  8\. Witthoft et al.^[@bibr7-2050313X19838946]^            Female   60    Alcoholic cirrhosis      Hematemesis                         GOV2         Cyanoacrylate   2                                                     Prophylaxis intubation   Bilateral PA     Supportive treatment   Recovery
  9\. Van Beek and van Erpecum^[@bibr8-2050313X19838946]^   Male     30    Portal vein thrombosis   Hematemesis                         IGV1         Cyanoacrylate   2                                                     N/A                      Bilateral PA     Supportive treatment   Died of abdominal sepsis
  10\. Robaina et al.^[@bibr9-2050313X19838946]^            Male     61    Cryptogenic cirrhosis    Elective sclerotherapy              GOV2         Cyanoacrylate   1.3                                                   24 h                     Bilateral PA     Supportive treatment   Recovery
  11\. Chew et al.^[@bibr10-2050313X19838946]^              Male     34    HBV cirrhosis            Hematemesis                         GOV2         Cyanoacrylate   4                                                     10 days                  Bilateral PA     Supportive treatment   Recovery
  12\. El-Essawy and Al-Harbi^[@bibr11-2050313X19838946]^   Female   40    HBV cirrhosis            Elective sclerotherapy              IGV1         Cyanoacrylate   6                                                     1 day                    Bilateral PA     N/A                    Recovery
  13\. Ashraf et al.^[@bibr12-2050313X19838946]^            Female   65    HCV cirrhosis            Coffee ground vomiting and melena   GOV2         Cyanoacrylate   12                                                    Immediately              Bilateral PA     CPR                    Died of massive pulmonary emboli
  14\. Javed and Salamat^[@bibr13-2050313X19838946]^        Female   60    HCV cirrhosis            Melena                              IGV1         Cyanoacrylate   12                                                    1 day                    Bilateral PA     Supportive treatment   Died of liver failure
  15\. Prytula et al.^[@bibr14-2050313X19838946]^           Male     11    Liver fibrosis           Hematemesis                         IGV1         Cyanoacrylate   1                                                     Shortly                  N/A              Supportive treatment   Recovery
  16\. Marco de Lucas et al.^[@bibr15-2050313X19838946]^    Male     58    HBV cirrhosis            UGIB                                IGV1         Cyanoacrylate   7                                                     24 h                     Bilateral PA     Supportive treatment   Recovery
  17 Our patient                                            Male     49    Alcoholic cirrhosis      UGIB                                GOV2         Cyanoacrylate   15.6                                                  24 h                     Right lower PA   Supportive treatment   Recovery

GV: gastric varix; GOV: gastroesophageal varix; IGV: isolated gastric varix; HBV: hepatitis B virus; HCV: hepatitis C virus; PA: pulmonary artery; CPR: cardiopulmonary resuscitation; UGIB: upper gastrointertinal bleeding.

Conclusion {#section4-2050313X19838946}
==========

This case report shows that pulmonary embolism may occur during endoscopic sclerotherapy of gastric varices and is usually related with the volume of cyanoacrylate glue injection.
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